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Abstract
Colorectal cancer (CRC) includes tumors in the right colon, left colon, and rectum, 
although they differ significantly from each other in aspects such as prognosis and 
treatment. Few previous mass spectrometry-based studies have analyzed differences 
in protein expression depending on the tumor location. In this study, we have used 
mass spectrometry-based proteomics to analyze plasma samples from 83 CRC pa-
tients to study if differences in plasma protein expression can be seen depending on 
primary tumor location (right colon, left colon, or rectum). Differences were stud-
ied between the groups both regardless of and according to tumor stage (II or III). 
Large differences in plasma protein expression were seen, and we found that plasma 
samples from patients with rectal cancer separated from samples from patients with 
colon cancer when analyzed by principal component analysis and hierarchical clus-
tering. Samples from patients with cancer in the right and left colon also tended to 
separate from each other. Pathway analysis discovered canonical pathways involved 
in lipid metabolism and inflammation to be enriched. This study will help to further 
define CRC as distinct entities depending on tumor location, as shown by the wide-
spread differences in plasma protein profile and dysregulated pathways.
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1 |  BACKGROUND
Colorectal cancer (CRC) is the third most common cancer 
worldwide and the second most common cause of cancer 
death, with over 1.8 million new cases and closer to 900 000 
deaths estimated to have occurred in 2018. CRC therefore 
accounts for 10% of the global cancer burden, and the bur-
den is expected to increase by 60% to more than 2.2 million 
new cases and 1.1 million deaths by 2030.1,2 CRC includes 
cancer in the colon, which is further divided into the right 
and left colon, and the rectum. Cancer in the right colon dif-
fers from cancer in the left colon, and rectal cancer differs 
from colon cancer in multiple ways.3 The boundary between 
the right and left colon, which is defined by embryological 
origin, is the distal transverse colon. Seeing as this is dif-
ficult to use in retrospective analyses, most studies use 
the splenic flexure as the boundary between cancer in the 
right colon and left colon, with tumors arising proximal to 
the splenic flexure being classified as right-sided and tu-
mors arising distal to the splenic flexure being classified as 
left-sided.4,5
Cancer in the right and left colon differ in multiple 
ways, with some proposing that they should be regarded 
as different entities.6,7 Right-sided colon cancer is more 
often seen in older people and women, and patients tend to 
present with more advanced tumor stage and more subtle 
symptoms.8,9 Several studies have also shown that right-
sided colon cancer has a worse prognosis than left-sided 
T A B L E  1  Top 20 plasma proteins with a Bonferroni-corrected P-value of less than .01 when all samples were compared
Accession
Peptide 
count
Unique 
peptides
Confidence 
score
ANOVA 
(P)
Bonferroni-
corrected P-values
Max fold 
change Power
Highest mean 
condition
Lowest mean 
condition
AUC (right 
colon/left colon)
AUC (right 
colon/rectum)
AUC (left 
colon/rectum) Protein name Gene name
Q92496 6 2 35.6 <.0001 <.0001 13.0 1.00 Right colon Rectum 0.67 0.97 0.94 Complement factor H-related 
protein 4
CFHR4
P08779;P02533 3 2 15.5 1.33E-15 2.98E-13 11.4 1.00 Right colon Rectum 0.72 0.98 0.95 Keratin_ type I cytoskeletal 16 KRT16
P35527 6 5 28.7 <.0001 <.0001 10.1 1.00 Right colon Rectum 0.73 1.00 0.98 Keratin_ type I cytoskeletal 9 KRT9
P13645;Q7Z3Y7;Q7Z3Y8;Q7Z3Y
9;Q7Z3Z0
6 5 36.0 <.0001 <.0001 7.8 1.00 Right colon Rectum 0.61 0.99 0.98 Keratin_ type I cytoskeletal 10 KRT10
Q9ULC5 5 3 23.0 <.0001 <.0001 6.3 1.00 Right colon Rectum 0.85 1.00 0.98 Long-chain-fatty-acid--CoA 
ligase 5
ACSL5
Q03591 15 2 131.6 3.69E-12 8.27E-10 6.2 1.00 Right colon Rectum 0.62 0.94 0.90 Complement factor H-related 
protein 1
CFHR1
P04264 7 2 39.0 2.98E-09 6.68E-07 5.3 1.00 Left colon Rectum 0.54 0.90 0.88 Keratin_ type II cytoskeletal 1 KRT1
Q9UIF8 4 2 19.5 <0.0001 <0.0001 4.6 1.00 Right colon Rectum 0.68 0.95 0.91 Bromodomain adjacent to zinc 
finger domain protein 2B
BAZ2B
Q3V6T2 15 6 70.1 <0.0001 <0.0001 4.3 1.00 Right colon Rectum 0.64 1.00 0.99 Girdin CCDC88A
A6NMZ7;P51570;Q13158;Q6NT55 5 2 24.3 <.0001 <.0001 4.3 1.00 Right colon Rectum 0.80 1.00 0.97 Collagen alpha-6(VI) chain COL6A6
H3BMM5 3 2 13.7 <.0001 <.0001 4.2 1.00 Right colon Rectum 0.60 0.98 0.97 Uncharacterized protein
P00746 3 2 12.0 <.0001 <.0001 3.8 1.00 Right colon Rectum 0.61 0.97 0.97 Complement factor D CFD
Q86UX7 7 2 37.3 8.29E-11 1.86E-08 3.8 1.00 Right colon Rectum 0.71 0.94 0.86 Fermitin family homolog 3 FERMT3
Q12805 9 8 51.7 <.0001 <.0001 3.4 1.00 Right colon Rectum 0.79 1.00 0.96 EGF-containing fibulin-like 
extracellular matrix protein 1
EFEMP1
O43866 7 5 38.1 <.0001 <.0001 3.4 1.00 Right colon Rectum 0.63 0.99 0.95 CD5 antigen-like CD5L
B1AJZ9 10 3 49.0 3.89E-15 8.70E-13 3.4 1.00 Right colon Rectum 0.71 0.96 0.92 Forkhead-associated domain-
containing protein 1
FHAD1
O75038 5 3 20.9 1.11E-16 2.49E-14 3.3 1.00 Right colon Rectum 0.72 0.97 0.90 1-phosphatidylinositol 
4_5-bisphosphate 
phosphodiesterase eta-2
PLCH2
Q9P2E3 9 2 55.8 4.80E-09 1.07E-06 3.1 1.00 Right colon Rectum 0.50 0.85 0.90 NFX1-type zinc finger-
containing protein 1
ZNFX1
Q6UB98 6 2 36.6 <.0001 <.0001 3.0 1.00 Right colon Rectum 0.72 0.98 0.95 Ankyrin repeat domain-
containing protein 12
ANKRD12
Q9Y4C1 4 3 21.0 <.0001 <.0001 2.9 1.00 Right colon Rectum 0.78 0.99 0.96 Lysine-specific demethylase 
3A
KDM3A
Note: The list with all significantly different proteins can be found in Table S3A.
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colon cancer, although the reason for this is unclear.10-12 
Rectal cancer has a greater risk of local recurrence as re-
section is harder due to anatomical constraints. It also has 
a greater risk of metastasizing to the lungs than colon can-
cer.13,14 However, the 5-year survival rates for colon and 
rectal cancer are similar, with rectal cancer actually having 
a slightly higher 5-year survival rate (66.6%) than colon 
cancer (63.6%).15 Differences between rectal and colon 
cancer are also apparent at the molecular level. Rectal 
tumors more often display mutations in genes such as 
tumor protein p53 (TP53), while colon tumors more often 
have mutations in genes including B-Raf proto-oncogene 
(BRAF).14,16 The consensus molecular subtypes (CMS) 
are a recent classification of CRC into four subtypes with 
distinguishing features considered the most robust clas-
sification system currently available for CRC. CMS1 tu-
mors, which are characterized by microsatellite instability 
(MSI), the CpG island methylator phenotype (CIMP), and 
hypermutation, were frequently right-sided. CMS2 tumors, 
which display higher chromosomal instability than CMS1 
and upregulation of WNT and MYC downstream targets, 
were mainly left-sided.17
Few previous mass spectrometry-based studies have 
analyzed differences in protein expression depending on 
tumor location.18 One study used mass spectrometry to 
analyze tissue samples from patients with cancer in the 
right and left colon and discovered that the expression of 
proteins involved in cellular energy metabolism, protein 
T A B L E  1  Top 20 plasma proteins with a Bonferroni-corrected P-value of less than .01 when all samples were compared
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ANOVA 
(P)
Bonferroni-
corrected P-values
Max fold 
change Power
Highest mean 
condition
Lowest mean 
condition
AUC (right 
colon/left colon)
AUC (right 
colon/rectum)
AUC (left 
colon/rectum) Protein name Gene name
Q92496 6 2 35.6 <.0001 <.0001 13.0 1.00 Right colon Rectum 0.67 0.97 0.94 Complement factor H-related 
protein 4
CFHR4
P08779;P02533 3 2 15.5 1.33E-15 2.98E-13 11.4 1.00 Right colon Rectum 0.72 0.98 0.95 Keratin_ type I cytoskeletal 16 KRT16
P35527 6 5 28.7 <.0001 <.0001 10.1 1.00 Right colon Rectum 0.73 1.00 0.98 Keratin_ type I cytoskeletal 9 KRT9
P13645;Q7Z3Y7;Q7Z3Y8;Q7Z3Y
9;Q7Z3Z0
6 5 36.0 <.0001 <.0001 7.8 1.00 Right colon Rectum 0.61 0.99 0.98 Keratin_ type I cytoskeletal 10 KRT10
Q9ULC5 5 3 23.0 <.0001 <.0001 6.3 1.00 Right colon Rectum 0.85 1.00 0.98 Long-chain-fatty-acid--CoA 
ligase 5
ACSL5
Q03591 15 2 131.6 3.69E-12 8.27E-10 6.2 1.00 Right colon Rectum 0.62 0.94 0.90 Complement factor H-related 
protein 1
CFHR1
P04264 7 2 39.0 2.98E-09 6.68E-07 5.3 1.00 Left colon Rectum 0.54 0.90 0.88 Keratin_ type II cytoskeletal 1 KRT1
Q9UIF8 4 2 19.5 <0.0001 <0.0001 4.6 1.00 Right colon Rectum 0.68 0.95 0.91 Bromodomain adjacent to zinc 
finger domain protein 2B
BAZ2B
Q3V6T2 15 6 70.1 <0.0001 <0.0001 4.3 1.00 Right colon Rectum 0.64 1.00 0.99 Girdin CCDC88A
A6NMZ7;P51570;Q13158;Q6NT55 5 2 24.3 <.0001 <.0001 4.3 1.00 Right colon Rectum 0.80 1.00 0.97 Collagen alpha-6(VI) chain COL6A6
H3BMM5 3 2 13.7 <.0001 <.0001 4.2 1.00 Right colon Rectum 0.60 0.98 0.97 Uncharacterized protein
P00746 3 2 12.0 <.0001 <.0001 3.8 1.00 Right colon Rectum 0.61 0.97 0.97 Complement factor D CFD
Q86UX7 7 2 37.3 8.29E-11 1.86E-08 3.8 1.00 Right colon Rectum 0.71 0.94 0.86 Fermitin family homolog 3 FERMT3
Q12805 9 8 51.7 <.0001 <.0001 3.4 1.00 Right colon Rectum 0.79 1.00 0.96 EGF-containing fibulin-like 
extracellular matrix protein 1
EFEMP1
O43866 7 5 38.1 <.0001 <.0001 3.4 1.00 Right colon Rectum 0.63 0.99 0.95 CD5 antigen-like CD5L
B1AJZ9 10 3 49.0 3.89E-15 8.70E-13 3.4 1.00 Right colon Rectum 0.71 0.96 0.92 Forkhead-associated domain-
containing protein 1
FHAD1
O75038 5 3 20.9 1.11E-16 2.49E-14 3.3 1.00 Right colon Rectum 0.72 0.97 0.90 1-phosphatidylinositol 
4_5-bisphosphate 
phosphodiesterase eta-2
PLCH2
Q9P2E3 9 2 55.8 4.80E-09 1.07E-06 3.1 1.00 Right colon Rectum 0.50 0.85 0.90 NFX1-type zinc finger-
containing protein 1
ZNFX1
Q6UB98 6 2 36.6 <.0001 <.0001 3.0 1.00 Right colon Rectum 0.72 0.98 0.95 Ankyrin repeat domain-
containing protein 12
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Q9Y4C1 4 3 21.0 <.0001 <.0001 2.9 1.00 Right colon Rectum 0.78 0.99 0.96 Lysine-specific demethylase 
3A
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Note: The list with all significantly different proteins can be found in Table S3A.
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folding, and oxidative stress varied between samples from 
the two locations.19 Another study revealed distinct pro-
tein expression between right- and left-sided colon can-
cer and identified several proteins that could be of use in 
predicting relapse in right- or left-sided colon cancer.20 
In this study, we have used the Ultra Performance Liquid 
Chromatography-Ultra Definition Mass Spectrometry 
(UPLC-UDMSE)-based proteomics to analyze plasma sam-
ples from 83 CRC patients who were divided into groups 
based on if they had tumors in the right colon, left colon, 
or rectum. The samples were compared between primary 
tumor locations, both regardless of and according to tumor 
stage (II or III), and plasma protein expression was ana-
lyzed. The aim of this study was to investigate whether dif-
ferences were seen in plasma protein expression between 
patients with tumors in the right colon, left colon, or rec-
tum. While a previous study has investigated how plasma 
protein expression changes during stage II and III CRC,21 
both depending on and regardless of tumor location, as far 
as we are aware, this study is the first to show that plasma 
protein profiles differ significantly between CRC patients 
depending on tumor location.
2 |  MATERIALS AND METHODS
2.1 | Patient samples
This study used preoperative plasma samples from a total of 
83 CRC patients with stage II or III cancer in the right colon, 
left colon, or rectum. Cancer staging was performed accord-
ing to the TNM staging system. Stage II cancer was defined 
as cases with a pT3-4 primary tumor but no regional lymph 
node or distant metastasis, while stage III cancer was defined 
as cases with regional lymph node metastasis but no distant 
metastasis. The patients underwent surgical resection with 
curative intent between 2000 and 2007. The patients included 
in this study were all newly diagnosed with stage II or III 
cancer. Patients with conditions including other types of can-
cer, a previous history of hereditary nonpolyposis colorectal 
T A B L E  2  Top 20 plasma proteins with a Bonferroni-corrected P-value of less than .01 when only stage II samples were compared
Accession
Peptide 
count
Unique 
peptides
Confidence 
score ANOVA (P) Bonferroni-corrected P-values
Max fold 
change Power
Highest mean 
condition
Lowest mean 
condition Protein name Gene name
P35527 6 5 28.7 7.95E-08 1.78E-05 10.7 1.00 Left colon stage II Rectum stage II Keratin_ type I cytoskeletal 9 KRT9
Q92496 6 2 35.6 7.17E-06 1.61E-03 8.4 1.00 Right colon stage II Rectum stage II Complement factor H-related protein 4 CFHR4
P08779;P02533 3 2 15.5 9.54E-06 2.14E-03 6.1 1.00 Right colon stage II Rectum stage II Keratin_ type I cytoskeletal 16 KRT16
P13645;Q7Z3Y7;Q7Z3Y8;Q7Z3Y9;Q7Z3Z0 6 5 36.0 8.28E-09 1.86E-06 5.6 1.00 Left colon stage II Rectum stage II Keratin_ type I cytoskeletal 10 KRT10
Q3V6T2 15 6 70.1 2.01E-10 4.50E-08 4.6 1.00 Right colon stage II Rectum stage II Girdin CCDC88A
Q9ULC5 5 3 23.0 9.65E-14 2.16E-11 4.6 1.00 Right colon stage II Rectum stage II Long-chain-fatty-acid--CoA ligase 5 ACSL5
P00746 3 2 12.0 3.12E-09 6.98E-07 4.3 1.00 Right colon stage II Rectum stage II Complement factor D CFD
O43866 7 5 38.1 1.97E-10 4.42E-08 4.0 1.00 Right colon stage II Rectum stage II CD5 antigen-like CD5L
A6NMZ7;P51570;Q13158;Q6NT55 5 2 24.3 1.94E-11 4.33E-09 4.0 1.00 Right colon stage II Rectum stage II Collagen alpha-6(VI) chain COL6A6
Q9UIF8 4 2 19.5 2.24E-06 5.01E-04 3.8 1.00 Right colon stage II Rectum stage II Bromodomain adjacent to zinc finger 
domain protein 2B
BAZ2B
Q92777 5 3 27.1 2.41E-05 5.40E-03 3.5 1.00 Right colon stage II Rectum stage II Synapsin-2 SYN2
H3BMM5 3 2 13.7 5.10E-08 1.14E-05 3.5 1.00 Right colon stage II Rectum stage II Uncharacterized protein
Q96PZ0 3 2 21.0 2.54E-05 5.70E-03 3.2 1.00 Right colon stage II Rectum stage II Pseudouridylate synthase 7 homolog PUS7
Q12805 9 8 51.7 1.81E-11 4.04E-09 3.2 1.00 Right colon stage II Rectum stage II EGF-containing fibulin-like extracellular 
matrix protein 1
EFEMP1
B1AJZ9 10 3 49.0 1.06E-06 2.38E-04 3.1 1.00 Right colon stage II Rectum stage II Forkhead-associated domain-containing 
protein 1
FHAD1
Q9Y4C1 4 3 21.0 6.88E-09 1.54E-06 3.0 1.00 Right colon stage II Rectum stage II Lysine-specific demethylase 3A KDM3A
O75038 5 3 20.9 1.99E-07 4.46E-05 2.9 1.00 Right colon stage II Rectum stage II 1-phosphatidylinositol 4_5-bisphosphate 
phosphodiesterase eta-2
PLCH2
Q9UK55 22 13 125.8 3.53E-05 7.92E-03 2.9 1.00 Right colon stage II Rectum stage II Protein Z-dependent protease inhibitor SERPINA10
Q8IV77 3 2 14.4 4.37E-07 9.78E-05 2.9 1.00 Right colon stage II Rectum stage II Cyclic nucleotide-gated cation channel 
alpha-4
CNGA4
P04070 6 4 29.2 4.30E-07 9.63E-05 2.7 1.00 Right colon stage II Rectum stage II Vitamin K-dependent protein C PROC
Note: The list with all significantly different proteins can be found in Table S3B.
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cancer (HNPCC), familial adenomatous polyposis (FAP), 
ulcerative colitis, Crohn's disease, or mucinous tumors were 
also excluded from this study. Plasma samples were stored at 
−80°C until processed as described below. The clinical data 
were obtained from patient records, the survival data from 
the Population Register Centre of Finland, and the cause of 
death for all the deceased from Statistics Finland. Written 
informed consent was obtained from all patients prior to 
collecting samples. This study was approved by the local 
Surgical Ethics Committee and carried out in accordance 
with the Declaration of Helsinki.
2.2 | Sample processing and digestion
The plasma samples were processed as described previ-
ously21,22 and as follows. All samples were thawed and 
top 12 protein depletion was performed with TOP12 
protein depletion spin columns (85  165, Pierce) accord-
ing to the manufacturer's instructions. After the total 
protein concentration was determined, plasma equivalent 
to 100  µg protein was aliquoted and dried. The samples 
were dissolved in 35 µL Tris buffer (50 mmol/L, pH 7.8, 
T1503, Sigma) containing 6M urea (51 459, Fluka), after 
which 1.8 µL of dithiothreitol (DTT, 200 mmol/L, V315B, 
Promega) was added. After the samples were shaken 
for 1  hour at room temperature, 7  µL of iodoacetamide 
(200  mmol/L, 57  670, Fluka) was added to each sample 
and they were returned to the shaker for another hour. 
After this, 7 µL of DTT (200 mmol/L) was added to each 
sample and the samples were again put on the shaker 
for 1  hour. The samples were subsequently diluted with 
270 µL mQ water per sample. Trypsin (V5280, Promega) 
was added at a ratio of 1:50 trypsin to protein. Digestion 
was carried out at 37°C overnight, and the next day C18 
spin columns (89 870, Pierce) were used to clean 30 µg of 
tryptic peptides per sample. These peptides were dissolved 
in 86 µL of 0.1% formic acid that contained 12.5 fmol/µL 
of Hi3 spike-in standard peptides (186 006 012, Waters) 
for quantification.
T A B L E  2  Top 20 plasma proteins with a Bonferroni-corrected P-value of less than .01 when only stage II samples were compared
Accession
Peptide 
count
Unique 
peptides
Confidence 
score ANOVA (P) Bonferroni-corrected P-values
Max fold 
change Power
Highest mean 
condition
Lowest mean 
condition Protein name Gene name
P35527 6 5 28.7 7.95E-08 1.78E-05 10.7 1.00 Left colon stage II Rectum stage II Keratin_ type I cytoskeletal 9 KRT9
Q92496 6 2 35.6 7.17E-06 1.61E-03 8.4 1.00 Right colon stage II Rectum stage II Complement factor H-related protein 4 CFHR4
P08779;P02533 3 2 15.5 9.54E-06 2.14E-03 6.1 1.00 Right colon stage II Rectum stage II Keratin_ type I cytoskeletal 16 KRT16
P13645;Q7Z3Y7;Q7Z3Y8;Q7Z3Y9;Q7Z3Z0 6 5 36.0 8.28E-09 1.86E-06 5.6 1.00 Left colon stage II Rectum stage II Keratin_ type I cytoskeletal 10 KRT10
Q3V6T2 15 6 70.1 2.01E-10 4.50E-08 4.6 1.00 Right colon stage II Rectum stage II Girdin CCDC88A
Q9ULC5 5 3 23.0 9.65E-14 2.16E-11 4.6 1.00 Right colon stage II Rectum stage II Long-chain-fatty-acid--CoA ligase 5 ACSL5
P00746 3 2 12.0 3.12E-09 6.98E-07 4.3 1.00 Right colon stage II Rectum stage II Complement factor D CFD
O43866 7 5 38.1 1.97E-10 4.42E-08 4.0 1.00 Right colon stage II Rectum stage II CD5 antigen-like CD5L
A6NMZ7;P51570;Q13158;Q6NT55 5 2 24.3 1.94E-11 4.33E-09 4.0 1.00 Right colon stage II Rectum stage II Collagen alpha-6(VI) chain COL6A6
Q9UIF8 4 2 19.5 2.24E-06 5.01E-04 3.8 1.00 Right colon stage II Rectum stage II Bromodomain adjacent to zinc finger 
domain protein 2B
BAZ2B
Q92777 5 3 27.1 2.41E-05 5.40E-03 3.5 1.00 Right colon stage II Rectum stage II Synapsin-2 SYN2
H3BMM5 3 2 13.7 5.10E-08 1.14E-05 3.5 1.00 Right colon stage II Rectum stage II Uncharacterized protein
Q96PZ0 3 2 21.0 2.54E-05 5.70E-03 3.2 1.00 Right colon stage II Rectum stage II Pseudouridylate synthase 7 homolog PUS7
Q12805 9 8 51.7 1.81E-11 4.04E-09 3.2 1.00 Right colon stage II Rectum stage II EGF-containing fibulin-like extracellular 
matrix protein 1
EFEMP1
B1AJZ9 10 3 49.0 1.06E-06 2.38E-04 3.1 1.00 Right colon stage II Rectum stage II Forkhead-associated domain-containing 
protein 1
FHAD1
Q9Y4C1 4 3 21.0 6.88E-09 1.54E-06 3.0 1.00 Right colon stage II Rectum stage II Lysine-specific demethylase 3A KDM3A
O75038 5 3 20.9 1.99E-07 4.46E-05 2.9 1.00 Right colon stage II Rectum stage II 1-phosphatidylinositol 4_5-bisphosphate 
phosphodiesterase eta-2
PLCH2
Q9UK55 22 13 125.8 3.53E-05 7.92E-03 2.9 1.00 Right colon stage II Rectum stage II Protein Z-dependent protease inhibitor SERPINA10
Q8IV77 3 2 14.4 4.37E-07 9.78E-05 2.9 1.00 Right colon stage II Rectum stage II Cyclic nucleotide-gated cation channel 
alpha-4
CNGA4
P04070 6 4 29.2 4.30E-07 9.63E-05 2.7 1.00 Right colon stage II Rectum stage II Vitamin K-dependent protein C PROC
Note: The list with all significantly different proteins can be found in Table S3B.
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2.3 | Ultra performance liquid 
chromatography-ultra definition mass 
spectrometry and quantification UPLC-
UDMSE
UPLC was performed as described previously21,22 and as 
follows. Four microliter of each sample (the equivalent 
to ~1.4  µg total protein) was injected to a nanoACQUITY 
UPLC system (Waters Corporation,) and TRIZAIC nano-
Tile 85 μm × 100 mm HSS-T3u wTRAP was used as a sepa-
ration device. As mentioned in Holm et al21: “Samples were 
loaded, trapped, and washed for two minutes with 8.0 µL 1% 
B and the analytical gradient used was as follows: 0-1 min-
utes 1% B, at 2  minutes 5% B, at 65  minutes 30% B, at 
78 minutes 50% B, at 80 minutes 85% B, at 83 minutes 85% 
B, at 84 minutes 1% B, and at 90 minutes 1% B with 450 nL/
min. Buffer A was 0.1% formic acid in water while buffer 
B was 0.1% formic acid in acetonitrile. Data were acquired 
in data-independent acquisition fashion using UDMSE mode 
with a Synapt G2-S HDMS (Waters Corporation).”
UDMSE data acquisition mode was used in this study to 
optimize the collision energies, which has previously been 
described by Distler et al.23 Briefly, in classical HDMSE, one 
fixed collision energy is applied to each individual ion mobil-
ity separation cycle, which results in under- or over-fragmen-
tation of precursor ions. Distler et al23 devised a strategy for 
using linear regression to specify drift-time specific collision 
energies for every drift-time bin of the IMS cycle, resulting 
in optimized energies for all precursors. Calibration was 
performed with sodium iodide clusters over a mass range of 
50-2500 m/z. A solution of 2 µg/µL sodium iodide in 50/50 
2-propanol/water was infused into the mass spectrometer. 
10% of the samples were run in triplicate and the median co-
efficient of variation (%CV) of the dataset was 4.36%.
2.4 | Data analysis
Data analysis and label-free quantification were performed 
as described previously.21,22,24 The raw files were imported 
to Progenesis QI for proteomics, version 4.1 (Nonlinear 
Dynamics).25 Post-acquisition mass correction was per-
formed when the raw data were imported, using a lock 
mass ion of M + H+ 556.2771 m/z, with leucine enkepha-
lin (C25H37O7, 1 ng/µL in 50:50 acetonitrile:water + 0,1% 
formic acid) having been previously infused into the refer-
ence sprayer at 300 nL/min for this. The default parameters 
were used for peak picking and alignment. The peptide iden-
tification was performed against Uniprot human FASTA se-
quences (release 2018_04). A chaperone protein ClpB (ClpB) 
protein sequence (CLPB_ECOLI (P63285)) was inserted for 
label-free quantification. “Fixed modification” at cysteine 
(carbamidomethyl) and “variable” at methionine (oxidation) 
were used. One missed cleavage for trypsin was allowed. The 
automatic settings for the fragment and peptide error toler-
ances were used, while the false discovery rate (FDR) was 
set to less than 2%. The default parameters for ion matching 
were used, which are as follows: one or more ion fragments 
per peptide, three or more fragments per protein, and one or 
more peptides per protein.
The proteins were grouped according to the parsimony 
principle, although it is known that due to over-stringency, 
Progenesis QI for proteomics does not follow a strict parsi-
monious approach.26 Therefore, if two proteins are found that 
share common peptides, the protein with fewer peptides will 
be subsumed into the protein with more peptides. If the cov-
erages of two or more proteins are equal, all the relevant pro-
teins will be listed under the lead protein that has the highest 
coverage/score. In this study, quantification was performed 
using the data of the lead identity peptide. For further details, 
see Nonlinear Dynamics’ website (www.nonli near.com).
2.5 | Further analysis
The differences between the groups were analyzed using 
the ANOVA test and p-values were corrected using the 
Bonferroni correction. Bonferroni-corrected ANOVA-
passing p-values of less than 0.01 were considered signifi-
cant to ensure stringent analysis. Data were normalized by 
Pareto scaling, and hierarchical clustering and principal 
component analysis were performed using Metaboanalyst, 
version 4.0.27,28 The feature “autoscaling” was further 
used during hierarchical clustering to generate heatmaps. 
Pathway analysis was performed with Ingenuity Pathway 
Analysis (IPA, build version 486068M, content version 
46  901  286, QIAGEN Bioinformatics).29 All proteins that 
passed the cutoff of an ANOVA P-value of less than .05 
were used for pathway analysis. Pathway analysis was per-
formed separately for all ANOVA-passing proteins for all 
samples, stage II samples, and stage III samples between 
two tumor locations at a time (right colon/left colon, right 
colon/rectum, and left colon/rectum), as IPA cannot perform 
comparisons between three groups simultaneously. The 
mass spectrometry proteomics data have been deposited to 
the ProteomeXchange Consortium via the PRIDE30,31 part-
ner repository with the dataset identifier  PXD013150 and 
10.6019/PXD013150.
3 |  RESULTS
3.1 | Protein identification and analysis
In this study, we analyzed plasma samples from 83 CRC 
patients that were divided into groups based on primary 
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tumor location (right colon, left colon, rectum). Detailed 
patient characteristics are given in Table S1. The samples 
were also divided into groups based on location and tumor 
stage (II or III). Twenty-seven patients had tumors in the 
right colon, 26 in the left colon, and 30 in the rectum. We 
quantified 224 proteins that contained two or more unique 
peptides and these 224 proteins were used for further 
analysis. These proteins with relevant data are given in 
Table S2.
3.2 | All samples
When all plasma samples regardless of tumor stage were 
compared according to tumor location, 125 proteins passed 
the cut-off of a Bonferroni-corrected ANOVA P-value of less 
than .01. The top 20 proteins according to fold change are 
given in Table 1, and all 125 proteins are given in Table S3A. 
The largest differences were seen between plasma protein 
expression in samples from patients with cancer in the right 
F I G U R E  1  Hierarchical clustering heatmap of Pareto-scaled proteins using only those proteins that passed the cutoff of Bonferroni-corrected 
ANOVA P-value of less than .01 when only stage II samples were compared. The heatmap shows that plasma samples from patients with colon 
and rectal cancer form distinct clusters. Additionally, samples from patients with tumors in the right or left colon also showed a tendency to cluster 
together, although with some overlap between these colon tumors
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colon and rectum. Levels of keratins, type I cytoskeletal 16 
(KRT16), 9 (KRT9), and 10 (KRT10), as well as comple-
ment factor H-related protein 4 (CFHR4) and 1 (CFHR1), 
had higher levels in plasma samples from patients with can-
cer in the right colon (with fold changes between 6.2-13.0). 
The plasma levels of long-chain-fatty-acid--CoA ligase 5 
(ACSL5, fold change of 6.3), an enzyme, were also higher in 
plasma samples from patients with cancer in the right colon.
The area under the curve (AUC) values was also calcu-
lated for the 125 proteins passing the cutoff of a Bonferroni-
corrected ANOVA P-value of less than .01 when all samples 
were compared. This was done by comparing the proteins be-
tween two tumor locations at a time (right colon/left colon, right 
colon/rectum, and left colon/rectum). The results are given in 
Table  S3A and further strengthen our findings that plasma 
protein expression is significantly different between patients 
with cancer in the colon and rectum, with multiple proteins 
reaching AUC values of > 0.9, increasing their confidence. 
The fold changes for all proteins between two tumor locations 
only (right colon/left colon, right colon/rectum, and left colon/
rectum) are given for reference in Table S4A.
Pareto scaling was performed and principal component 
analysis (PCA) biplots and hierarchical clustering heatmaps 
were generated. The PCA when all proteins were consid-
ered is given in Figure S1. The heatmap when only proteins 
that passed the cutoff of a Bonferroni-corrected ANOVA P-
value of less than .01 were considered is given in Figure S2. 
Figure S2 shows that samples from patients with rectal cancer 
cluster together, although a few of these samples clustered to-
gether with samples from patients with cancer in the left colon.
3.3 | Stage II samples
The samples from patients with stage II CRC only were also 
analyzed according to tumor location, and 46 proteins passed 
T A B L E  3  Top 20 plasma proteins with a Bonferroni-corrected P-value of less than .01 when only stage III samples were compared
Accession
Peptide 
count
Unique 
peptides
Confidence 
score ANOVA (P)
Bonferroni-corrected  
P-values Max fold change Power Highest mean condition
Lowest mean 
condition Protein name Gene name
P08779;P02533 3 2 15.5 1.83E-14 4.10E-12 45.6 1.00 Right colon stage III Rectum stage III Keratin_ type I cytoskeletal 16 KRT16
Q92496 6 2 35.6 1.52E-14 3.41E-12 41.2 1.00 Right colon stage III Rectum stage III Complement factor H-related protein 4 CFHR4
Q03591 15 2 131.6 1.67E-12 3.73E-10 27.9 1.00 Right colon stage III Rectum stage III Complement factor H-related protein 1 CFHR1
P35527 6 5 28.7 5.55E-14 1.24E-11 18.2 1.00 Right colon stage III Rectum stage III Keratin_ type I cytoskeletal 9 KRT9
P13645;Q7Z3Y7;Q7Z3Y8;Q7Z3Y9;Q7Z3Z0 6 5 36.0 <.0001 <.0001 15.2 1.00 Right colon stage III Rectum stage III Keratin_ type I cytoskeletal 10 KRT10
Q9ULC5 5 3 23.0 <.0001 <.0001 9.5 1.00 Right colon stage III Rectum stage III Long-chain-fatty-acid--CoA ligase 5 ACSL5
Q9UIF8 4 2 19.5 1.18E-12 2.64E-10 5.9 1.00 Right colon stage III Rectum stage III Bromodomain adjacent to zinc finger 
domain protein 2B
BAZ2B
H3BMM5 3 2 13.7 <.0001 <.0001 5.8 1.00 Left colon stage III Rectum stage III Uncharacterized protein
P04264 7 2 39.0 1.04E-07 2.33E-05 5.6 1.00 Right colon stage III Rectum stage III Keratin_ type II cytoskeletal 1 KRT1
Q86UX7 7 2 37.3 1.05E-08 2.36E-06 5.4 1.00 Right colon stage III Rectum stage III Fermitin family homolog 3 FERMT3
A6NMZ7;P51570;Q13158;Q6NT55 5 2 24.3 1.11E-16 2.49E-14 4.6 1.00 Right colon stage III Rectum stage III Collagen alpha-6(VI) chain COL6A6
Q6UB98 6 2 36.6 <.0001 <.0001 4.3 1.00 Right colon stage III Rectum stage III Ankyrin repeat domain-containing 
protein 12
ANKRD12
Q3V6T2 15 6 70.1 1.01E-13 2.25E-11 4.1 1.00 Right colon stage III Rectum stage III Girdin CCDC88A
B1AJZ9 10 3 49.0 3.69E-11 8.27E-09 3.8 1.00 Right colon stage III Rectum stage III Forkhead-associated domain-
containing protein 1
FHAD1
Q12805 9 8 51.7 4.45E-14 9.97E-12 3.8 1.00 Right colon stage III Rectum stage III EGF-containing fibulin-like 
extracellular matrix protein 1
EFEMP1
O75038 5 3 20.9 2.17E-10 4.86E-08 3.7 1.00 Right colon stage III Rectum stage III 1-phosphatidylinositol 
4_5-bisphosphate phosphodiesterase 
eta-2
PLCH2
P00746 3 2 12.0 2.38E-09 5.32E-07 3.4 1.00 Right colon stage III Rectum stage III Complement factor D CFD
Q8N841 6 2 26.9 3.14E-06 7.02E-04 3.4 1.00 Right colon stage III Rectum stage III Tubulin polyglutamylase TTLL6 TTLL6
Q92698 3 2 16.5 3.93E-09 8.81E-07 3.3 1.00 Left colon stage III Rectum stage III DNA repair and recombination protein 
RAD54-like
RAD54L
P59047 4 3 21.8 5.08E-06 1.14E-03 3.3 1.00 Right colon stage III Rectum stage III NACHT_ LRR and PYD domains-
containing protein 5
NLRP5
Note: The list with all significantly different proteins can be found in Table S3C.
   | 5229HOLM et aL.
the cut-off of a Bonferroni-corrected ANOVA P-value of less 
than .01 (Table S3B). The top 20 proteins according to fold 
change are shown in Table 2. Again, the greatest differences 
were seen between samples from patients with stage II cancer 
in the right colon or rectum. The protein with the largest fold 
change (10.7) was KRT9, with higher levels in samples from 
patients with cancer in the left colon compared to the rectum. 
CFHR4 (fold change of 8.4) had higher levels in samples 
from patients with cancer in the right colon compared to the 
rectum. The fold changes for all proteins compared between 
two tumor locations only are given in Table S4B.
PCA biplots and hierarchical clustering heatmaps were 
generated using stage II samples only with Pareto-scaled 
data. The PCA when all proteins were considered is given 
in Figure  S3. The heatmap when only the proteins that 
passed the cut-off of a Bonferroni-corrected ANOVA P-
value of less than .01 were considered is given in Figure 1. 
As seen in Figure  1, the plasma samples from patients 
with rectal cancer cluster together, while samples from 
patients with colon cancer form a separate cluster. While 
there is a tendency of samples from patients with tumors 
in the right or left colon to cluster together depending on 
tumor location, some overlap can be seen between the 
colon tumors.
3.4 | Stage III samples
When plasma samples from patients with stage III CRC were 
compared according to tumor location, 92 proteins passed the 
cut-off of a Bonferroni-corrected ANOVA P-value of less 
than .01 (Table S3C). The top 20 proteins according to fold 
change are shown in Table 3. The top three proteins, KRT16 
(with a fold change of 45.6), CFHR4 (with a fold change of 
41.2), and CFHR1 (with a fold change of 27.9), all displayed 
higher plasma levels in samples from patients with stage III 
T A B L E  3  Top 20 plasma proteins with a Bonferroni-corrected P-value of less than .01 when only stage III samples were compared
Accession
Peptide 
count
Unique 
peptides
Confidence 
score ANOVA (P)
Bonferroni-corrected  
P-values Max fold change Power Highest mean condition
Lowest mean 
condition Protein name Gene name
P08779;P02533 3 2 15.5 1.83E-14 4.10E-12 45.6 1.00 Right colon stage III Rectum stage III Keratin_ type I cytoskeletal 16 KRT16
Q92496 6 2 35.6 1.52E-14 3.41E-12 41.2 1.00 Right colon stage III Rectum stage III Complement factor H-related protein 4 CFHR4
Q03591 15 2 131.6 1.67E-12 3.73E-10 27.9 1.00 Right colon stage III Rectum stage III Complement factor H-related protein 1 CFHR1
P35527 6 5 28.7 5.55E-14 1.24E-11 18.2 1.00 Right colon stage III Rectum stage III Keratin_ type I cytoskeletal 9 KRT9
P13645;Q7Z3Y7;Q7Z3Y8;Q7Z3Y9;Q7Z3Z0 6 5 36.0 <.0001 <.0001 15.2 1.00 Right colon stage III Rectum stage III Keratin_ type I cytoskeletal 10 KRT10
Q9ULC5 5 3 23.0 <.0001 <.0001 9.5 1.00 Right colon stage III Rectum stage III Long-chain-fatty-acid--CoA ligase 5 ACSL5
Q9UIF8 4 2 19.5 1.18E-12 2.64E-10 5.9 1.00 Right colon stage III Rectum stage III Bromodomain adjacent to zinc finger 
domain protein 2B
BAZ2B
H3BMM5 3 2 13.7 <.0001 <.0001 5.8 1.00 Left colon stage III Rectum stage III Uncharacterized protein
P04264 7 2 39.0 1.04E-07 2.33E-05 5.6 1.00 Right colon stage III Rectum stage III Keratin_ type II cytoskeletal 1 KRT1
Q86UX7 7 2 37.3 1.05E-08 2.36E-06 5.4 1.00 Right colon stage III Rectum stage III Fermitin family homolog 3 FERMT3
A6NMZ7;P51570;Q13158;Q6NT55 5 2 24.3 1.11E-16 2.49E-14 4.6 1.00 Right colon stage III Rectum stage III Collagen alpha-6(VI) chain COL6A6
Q6UB98 6 2 36.6 <.0001 <.0001 4.3 1.00 Right colon stage III Rectum stage III Ankyrin repeat domain-containing 
protein 12
ANKRD12
Q3V6T2 15 6 70.1 1.01E-13 2.25E-11 4.1 1.00 Right colon stage III Rectum stage III Girdin CCDC88A
B1AJZ9 10 3 49.0 3.69E-11 8.27E-09 3.8 1.00 Right colon stage III Rectum stage III Forkhead-associated domain-
containing protein 1
FHAD1
Q12805 9 8 51.7 4.45E-14 9.97E-12 3.8 1.00 Right colon stage III Rectum stage III EGF-containing fibulin-like 
extracellular matrix protein 1
EFEMP1
O75038 5 3 20.9 2.17E-10 4.86E-08 3.7 1.00 Right colon stage III Rectum stage III 1-phosphatidylinositol 
4_5-bisphosphate phosphodiesterase 
eta-2
PLCH2
P00746 3 2 12.0 2.38E-09 5.32E-07 3.4 1.00 Right colon stage III Rectum stage III Complement factor D CFD
Q8N841 6 2 26.9 3.14E-06 7.02E-04 3.4 1.00 Right colon stage III Rectum stage III Tubulin polyglutamylase TTLL6 TTLL6
Q92698 3 2 16.5 3.93E-09 8.81E-07 3.3 1.00 Left colon stage III Rectum stage III DNA repair and recombination protein 
RAD54-like
RAD54L
P59047 4 3 21.8 5.08E-06 1.14E-03 3.3 1.00 Right colon stage III Rectum stage III NACHT_ LRR and PYD domains-
containing protein 5
NLRP5
Note: The list with all significantly different proteins can be found in Table S3C.
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cancer in the right colon than the rectum. The fold changes 
for all proteins between two tumor locations only are given 
in Table S4C.
PCA biplots and hierarchical clustering heatmaps were 
generated using Pareto-scaled data. The PCA when all pro-
teins were considered is given in Figure  2 and shows that 
plasma samples from patients with rectal cancer mostly sep-
arate from plasma samples from patients with right- or left-
sided colon cancer, which overlap more. The heatmap when 
only the proteins that passed the cut-off of a Bonferroni-
corrected ANOVA p-value of less than 0.01 were considered 
were considered is given in Figure  3, and similar to when 
only stage II samples were mapped, shows that samples from 
patients with rectal cancer form a distinct group. The plasma 
samples from patients with stage III tumors in the right or left 
colon also had a tendency to separate, although some overlap 
was seen (Figure 3).
3.5 | Pathway analysis
When the ANOVA-passing proteins for all samples were an-
alyzed by IPA between two tumor locations (right colon/left 
colon, right colon/rectum, and left colon/rectum) at a time, 
the top five canonical pathways enriched in all groups were 
LXR/RXR activation, acute phase response signaling, the 
complement system, FXR/RXR activation, and the coagula-
tion system (Figure S4). The same analysis was carried out 
for stage II samples, and the top five canonical pathways in 
all comparisons were the complement system, acute phase 
response signaling, LXR/RXR activation, FXR/RXR activa-
tion, and the coagulation system (Figure S5). For stage III 
samples, the top five canonical pathways enriched in all com-
parisons were LXR/RXR activation, the complement system, 
acute phase response signaling, FXR/RXR activation, and 
the coagulation system (Figure S6).
4 |  DISCUSSION
In this study, we observed widespread differences in 
plasma protein expression depending on primary tumor lo-
cation, both when samples were analyzed regardless of and 
according to tumor stage (II or III). In all three groups (all 
samples, stage II only, and stage III only), the plasma levels 
of CFHR4 (AUC of 0.97 when samples from patients with 
cancer in the right colon and rectum were compared) and 
ACSL5 (AUC of 1 between these samples) were found to 
be much higher in samples from patients with cancer in the 
right colon compared to the rectum (Table S3). In samples 
F I G U R E  2  PCA biplot showing stage 
III samples only when all Pareto-scaled 
proteins were considered
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from patients with stage III cancer, levels of CFHR4 were 
over 40 times higher in samples from patients with can-
cer in the right colon (Table S3C). Levels of CFHR1 were 
also significantly higher in the same samples when all 
and only stage III samples were compared (Table S3A,C). 
The expression of complement system components is in-
creased in cancer, and activation of the complement system 
has been shown to promote tumor growth in the context 
of inflammation.32,33 Our findings therefore indicate that 
inflammation may be more important in driving carcino-
genesis in the right colon than rectum.
The biggest differences in plasma protein expression were 
seen between samples from patients with cancer in the right 
colon compared to the rectum (Table S3), an understandable 
finding, as these locations are anatomically the furthest from 
each other. However, there were also significant differences 
in plasma protein expression between samples from patients 
with cancer in the right and left colon (Table S4). Tumors in 
F I G U R E  3  Hierarchical clustering heatmap of Pareto-scaled proteins using only those proteins that passed the cutoff of Bonferroni-corrected 
ANOVA P-value of less than .01 when only stage III samples were compared. This heatmap also shows that plasma samples from patients with 
colon and rectal cancer form distinct clusters, and that samples from patients with right- or left-sided colon tumors also form separate clusters, to 
some extent
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the right and left colon follow separate pathways of carcino-
genesis as they display different molecular features. Right-
sided tumors more frequently display MSI and CIMP, while 
left-sided tumors are more often characterized by chromo-
somal instability and mutations in genes such as TP53.4,34 
Additionally, tumors in the right colon also tend to display 
an increased infiltration of immune cells compared to tumors 
in the left colon, something which may have contributed to 
the differences in plasma protein expression, such as between 
complement components, observed in this study (Table S3).35
Pathway analysis by IPA found multiple canonical path-
ways to be enriched in this dataset, with the top five path-
ways enriched being the same regardless of tumor location 
or stage (Figures S4-S6). The enrichment of pathways such 
as LXR/RXR and FXR/RXR activation point to altered lipid 
metabolism, as LXR/RXR and FXR/RXR heterodimers have 
important roles in lipid and bile acid metabolism.36-38 The 
observed enrichment of pathways involved in lipid metabo-
lism may be affected by factors such as bile acid concentra-
tion, which differs between the right and left colon.39 Higher 
levels of ACSL5 were seen in samples from patients with 
cancer in the right colon compared to the rectum when all 
samples were analyzed (AUC of 1; Table 1). ACSL5 is an 
enzyme involved in lipid metabolism,40 and the differences 
in ACSL5 levels may have contributed to the enrichment of 
pathways such as LXR/RXR and FXR/RXR activation seen 
(Fig. S4B). The enrichment of pathways such as acute phase 
response signaling and the complement system indicate in-
flammation as having different roles in CRC depending on 
tumor location, something that is further supported by our 
findings that plasma levels of proteins such as complement 
differ depending on tumor location (Table S3).
In this study, the plasma proteomic profiles of patients 
with rectal cancer were found to be significantly different 
from those of patients with colon cancer. It has been sug-
gested that colon and rectal tumors follow separate pathways 
of carcinogenesis due to the different mutations commonly 
seen in colon and rectal cancer, indicating that they select 
for mutations in distinct signaling pathways.14 The results 
of a study by Kapiteijn et al16 indicated that the p53 path-
way is more important in rectal than colon cancer. Their 
study also found that rectal tumors were more often positive 
for nuclear ß-catenin than colon tumors, although this find-
ing was not associated with the presence of a mutation in 
the adenomatous polyposis coli (APC) gene. Another study 
found that mutations in the KRAS proto-oncogene (KRAS) 
were more commonly detected in colon tumors than rec-
tal tumors, and that the number of mutations detected was 
higher in colon tumors when compared to rectal tumors, 
further strengthening the theory that the pathways to car-
cinogenesis differ for colon and rectal tumors.41 Different 
pathways to carcinogenesis and the presence of different 
mutations in colon and rectal tumors likely affects plasma 
protein expression. This may help explain the differences in 
plasma protein profiles between samples from patients with 
cancer in the colon and rectum seen in the current study.
Previous mass spectrometric studies have mainly focused 
on identifying new proteins of use for the diagnosis and early 
detection of CRC and have focused on comparing samples 
from CRC patients and healthy controls.42-44 Several studies 
have investigated differences in protein expression between 
CRC in different locations and studied the expression of spe-
cific proteins in tissue samples using immunohistochemis-
try.45-49 In this study, we chose to analyze plasma samples from 
CRC patients only, without the inclusion of healthy controls, 
due to the paucity of such studies. A couple of recent studies 
have further investigated the differences between right- and 
left-sided colon cancer. One study using plasma metabolomic 
profiling found significant differences between right- and left-
sided colon cancer, with six metabolites identified as potential 
biomarkers for tumor location.50 A comparative proteog-
enomic study found distinct mutations and proteins between 
right-sided colon cancer, left-sided colon cancer, and rectal 
cancer.51 Another study investigated plasma protein expres-
sion during CRC progression from stage II to III and showed 
that there are both differences and overlap in plasma protein 
expression during cancer progression.21 However, this study 
did not compare plasma protein profiles depending solely on 
primary tumor location, which is the focus of the current study.
The aim of this study was to establish if plasma protein 
expression differed in a tumor location-specific manner. This 
pilot study did not aim to identify candidates for new bio-
markers for the diagnosis of CRC, as the current methods of 
diagnosis, involving colonoscopy and biopsy, are more spe-
cific than measuring the levels of plasma proteins. The plasma 
proteins identified in this study were also not tumor-derived 
and are therefore non-specific for CRC, as their concentra-
tions can be elevated due to other factors and conditions than 
CRC. This decreases their value as diagnostic markers, and 
their diagnostic value has subsequently not been validated.
The results of this study show that plasma protein ex-
pression is distinct depending on primary tumor location 
and can clearly classify colon and rectal tumors, and, to a 
lesser extent, right- and left-sided colon tumors. This study 
was strengthened by the relatively large number of samples 
analyzed, although it was limited by the lack of CRC tumor 
tissues studied simultaneously, which would have enabled the 
comparison of plasma protein expression with tissue protein 
expression. In future studies, we aim to analyze and compare 
protein expression in tumor tissue samples based on location, 
as well as further investigate the proteins identified here. The 
findings presented in this study will help to further define 
colon and rectal tumors (and to a lesser extent, right- and 
left-sided colon tumors) as separate entities as shown by the 
widespread differences in plasma protein profile and dysreg-
ulated pathways. Additionally, they also provide a basis for 
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future studies aiming to continue the investigation of the dis-
tinct disease entities that constitute CRC.
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